Wijnegem, Belgium, July 26th 2016: Novosanis announced today their collaboration with ImevaX, a biopharmaceutical company based in Munich, Germany. ImevaX developed a vaccine against the pathogen Helicobacter pylori (H. pylori) that can cause chronic stomach sores and ulcers potentially leading to gastric cancer. Novosanis will supply the VAX-ID™ device that allows for a standardized and accurate injection of the vaccine for their clinical trials.
Munich (Germany), October 28, 2015: ImevaX GmbH, a specialist in developing vaccines against pathogens of chronic infectious diseases, especially H. pylori infections, announced today the appointment of Dr Marie Roskrow as Chief Executive Officer and Staph Leavenworth Bakali as Chairman of the Supervisory Board.
Munich (Germany): ImevaX GmbH, a specialist in vaccines against pathogens of chronic infectious diseases, especially in H. pylori infections, announced today that KfW has joined the company’s 2014 Series A investor syndicate through a second closing of the financing.
Munich (Germany): ImevaX GmbH, a specialist in vaccines against pathogens of chronic infectious diseases, announces today the completion of a EUR 7.5 million Series A financing round. The round was led by Wellington Partners. Co-lead investors were BioMedPartners with their BioMedInvest-II LP fund, EMBL Ventures and Santo Venture Capital. ImevaX is a 2014 spin-out from the Technische Universität München (TUM) and has been recently awarded a EUR 5.9 million financing from the GO-Bio Phase II program of the Federal Ministry of Education and Research (BMBF).
Munich (Germany): ImevaX GmbH commenced its research and development activities in their own premises in Munich on Sep. 1st, 2014. With this step, ImevaX realized a successful spin-out from the Technische Universität München (TUM). A key factor for the success of the founder Professor Markus Gerhard and his team, is the long-standing support from the Institute of Medical Microbiology, Immunology and Hygiene at the TUM under the leadership of Professor Dirk Busch and funding from the Federal Ministry of Education and Research (BMBF), which will be continued with EURO 5.9 million under the GO Bio Phase II program from BMBF.